Abbott Drops ZoMaxx Stent In Favor Of Xience On Trial Results Slated For TCT

Following a review of its most recent trial data, Abbott has decided to refocus its drug-eluting stent development efforts on its recently acquired Xience V system and drop its in-house ZoMaxx stent program